Clinical Trials Logo

Synucleinopathy clinical trials

View clinical trials related to Synucleinopathy.

Filter by:
  • None
  • Page 1

NCT ID: NCT06460038 Not yet recruiting - Parkinson's Disease Clinical Trials

Tenapanor in Synucleinopathy-Related Constipation

Start date: December 2024
Phase: Phase 2
Study type: Interventional

Investigation of tenapanor as a potential treatment for synucleinopathy-associated constipation

NCT ID: NCT04534023 Recruiting - Clinical trials for Rapid Eye Movement Sleep Behavior Disorder

A Clinical Study of the Efficacy of Idebenone in the Treatment of iRBD Into Synucleinopathies

Start date: September 1, 2020
Phase: Phase 2
Study type: Interventional

142 cases of patients with iRBD will be recruited from the neurology department of Ruijin Hospital, th second Affiliated Hospital of Soochow University and wuhan Union Hospital. After the informed consent was signed, they were divided into a trial group and a control group randomly. Each group contains 71 cases. The patients in the trial group will be treated with Idebenone, while the patients in the control group was treated with placebo. Both groups of subjects will be treated for 5 years, and patients will be followed-up and evaluated in the first year, 3 years and 5 years after treatment. The observations include the MDS-UPDRS questionnaires evaluation, blood biomarker measurements and fMRI or PET-MR examination to make sure whether the patients has converted to synucleinopathies. Study hypothesis: Idebenone therapy for patients with iRBD is safe and effective in delaying disease progression into synucleinopathies.